Goldman Sachs
CNTX icon

Goldman Sachs’s Context Therapeutics CNTX Stock Holding History

Goldman Sachs’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.86K Sell
12,389
-274,910
-96% -$557K ﹤0.01% 6490
2026
Q1 		$753K Buy
+287,299
New +$671K ﹤0.01% 5303

Other funds holding CNTX

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Goldman Sachs's CNTX Position: Q2 2026 in Review

Goldman Sachs reduced its Context Therapeutics (CNTX) stake by 96% in Q2 2026, selling an estimated $557K and leaving 12,389 shares worth $6.86K. The position accounts for ﹤0.01% of the portfolio, ranked #6490.

Goldman Sachs first reported a position in CNTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $753K in Q1 2026. 79 funds tracked by Wall St. Rank hold CNTX as of Q2 2026.

  • Goldman Sachs held 12,389 shares of Context Therapeutics worth $6.86K as of Q2 2026.
  • Goldman Sachs sold 274,910 Context Therapeutics shares in Q2 2026, an estimated $557K.
  • Context Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #6490 holding.
  • Goldman Sachs first reported a position in Context Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Goldman Sachs's Context Therapeutics position peaked at $753K in Q1 2026.
  • 79 funds tracked by Wall St. Rank held Context Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.